A/Prof David Tan Shao Peng
National University Cancer Institute Singapore
Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS)
Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, NUS
Associate Chairman Medical Board (Research), National University Hospital (NUH)
Head, Innovation Transfer Office (Research Office), National University Health System (NUHS)
Dr David Tan is a consultant medical oncologist and clinician scientist at the National University Cancer Institute, Singapore. His primary clinical and research interests are in gynaecological (ovarian, endometrial and cervical) cancers and the development of novel anti-cancer therapeutic agents.
Dr Tan graduated with a BSc in Experimental Pathology (1st Class Honours) and MBBS with Distinction from Guy’s, King’s and St Thomas’ School of Medicine, University of London, UK. He undertook training in internal medicine at Hammersmith Hospital and Guy’s and St Thomas’ Hospitals in London, and obtained his MRCP(UK) in 2005. In that same year, he was awarded a Cancer Research UK (CRUK) Clinical Research Fellowship at The Institute of Cancer Research (the academic partner institution of The Royal Marsden Hospital), London, where he did research in ovarian and breast cancers and obtained his PhD in Oncology. He subsequently completed his specialist training in Medical Oncology at The Royal Marsden Hospital, London. After working in the Drug Development Unit at The Royal Marsden Hospital/ Institute of Cancer Research, he went on to complete another fellowship at the Princess Margaret Cancer Centre, University of Toronto, Canada, in Drug Development and Gynaecologic Oncology before returning back to Singapore.
In addition to his clinical and academic duties, he is currently also the Associate Chairman Medical Board for Research at the National University Hospital, Singapore and Head of the Innovation Transfer Office at National University Health Systems (NUHS). He is also a member of the Novel Agents Committee for Cancer (NACC) at the Experimental Therapeutics Centre in A*STAR Singapore.